HER2 Breast Cancer

When patients with locally advanced or metastatic soft tissue sarcoma do not respond to standard chemotherapy, they face a difficult situation.

Patients who recived olaparib after a median follow-up of 2.5 years revealed a 42% reduction in invasive disease–free survival, including local and metastatic recurrence of breast cancer, other new cancers, and death due to any cause.

In an interview with Targeted Oncology, Rachel Wuerstein, MD, discussed the implications of the KAMILLA trial and the benefit of T-DM1. Wuerstein also discussed the data that show TDM1’s potential use for patients with HER2-positive metastatic breast cancer beyond the standard-of-care second-line setting.

A prospective analysis demonstrated a trend toward worse prognosis for patients with metastatic breast cancer who were initially HER2 negative and switched to HER2 positive treated with HER2-directed therapies compared with those who were HER2 positive at diagnosis.

Strategies for treating patients with HER2-positive breast cancer and metastatic brain lesions was a topic discussed between William J. Gradishar, MD, and a group of peers during a Targeted Oncology Case-Based Roundtable event.

Adding paclitaxel to the combination of trastuzumab and pertuzumab was associated with pathologic complete response and invasive disease-free survival in patients with HER2-positive breast cancer compared with the doublet alone.

Adjuvant trastuzumab is showing promising long-term results in patients with HER2-positive early breast cancer, a population that is representative of most patients seen in clinical practice.

During a Targeted Oncology Case-Based Roundtable event, Joyce A. O’Shaughnessy, MD, discussed the case of a 63-year-old woman with HER2-positive breast cancer.

Treatment with [vic-]trastuzumab duocarmazine (SYD985) demonstrated a statistically significant improvement in progression-free survival compared with physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP study, according to a press release from Byondis B.V.

Results from a phase 2 trial of patients with HER2-positive breast comparing TCbH alone and TCbH with pyrotinib showed significant improvement when adding pyrotinib, according to data presented at ASCO.

Utilizing a de-escalation of treatment strategy, researchers found a high response and significant results among patients with HER2+ breast cancer.

Pertuzumab, trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer showed comparable pathologic complete response with docetaxel, carboplatin, trastuzumab, and pertuzumab with less toxicities.

Overall survival was maintained, and even improved, in patients with pretreated HER2-positive breast cancer receiving tucatinib plus trastuzumab and capecitabine versus placebo.

In a pharmacokinetic analysis of the first 15 patients in the phase 2 TBCRC049 study, researchers saw the first evidence for concentrations of tucatinib and ONT-993 in the cerebral spinal fluid of patients with HER2+ metastatic breast cancer with newly diagnosed leptomeningeal metastasis.

Ingrid Mayer, MD, MSCI, presents the case of a patient with high-risk HR+/HER2+ breast cancer who develops recurrence after a long disease-free interval.

Thomas Bachelot, MD, PhD, discusses therapies available for patients with HER2-positive breast cancer and brain metastases.

A standing question for oncologists is what to do for patients with tumors smaller than 2 cm. The question led to a debate on whether to administer neoadjuvant chemotherapy to patients with T1c hormone receptor–negative, HER2-positive breast cancer during the 38th Annual Miami Breast Cancer Conference.

Experts in the management of breast cancer review some trials leading to the future of personalized treatment for HER2+ breast cancer.

Andrew Seidman, MD, follows the patient after TCHP therapy and discusses the risk of recurrence with the experts.

Ingrid Mayer, MD, MSCI, and panel share the benefits of subcutaneous HP instead of IV HP therapy, particularly for the patients’ quality of life.

The panel of experts reviews the use dual HER2-targeted therapy in HER2+ breast cancer.

Experts in breast cancer management discuss the use of anthracycline and risk of the cardiac toxicities.

Charles Powell, MD, MBA, discusses the questions surrounding pulmonary toxicities when using anti-HER2 monoclonal antibodies such as trastuzumab deruxtecan for patients with HER2-positive metastatic breast cancer.

In an interview with Targeted Oncology, Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses HER2-positive metastatic breast cancer innovations, treatments, and upcoming studies.

Distinct gene signatures and BRCAness may correlate with pathologic complete response and invasive disease-free survival in patients with HER2-positive breast cancer treated with trastuzumab and pertuzumab with or without paclitaxel.